Fig 2: Kaplan–Meier survival curves for 16 differentially expressed mRNAs associated with overall survival in pheochromocytoma and paraganglioma. Sixteen DEmRNAs are presented (p<0.05): ACAA1, ANKRD36, CCNO, PTPRJ, ENOSF1, IREB2, KIAA1958, RCAN3, MCM10, MED12, NKX3-1, TTC38, NTNG1, ORAI2, VPS378, and EPHA2. The initial pathological diagnosis of patients was set as day 0. Horizontal axis represents overall survival time (days) and vertical axis represents survival probability.

Fig 3: ceRNA network and regulatory axes. (A) A regulatory lncRNA–miRNA–mRNA ceRNA network in PCPG patients. Red: downregulated. Green: upregulated. Diamond shape: lncRNA. Rounded rectangle: miRNA. Triangle: mRNA. ceRNA: competitive endogenous RNA; PCPG: pheochromocytoma and paraganglioma. (B) Two lncRNA–miRNA–mRNA axes in the ceRNA network. (C) The expression of AP001486.2 was positively correlated with RCAN3 (R=0.46, p=1.4×10-10), whereas the expression of AP006333.2 was positively correlated with PTPRJ (R=0.53, p=2.2×10-14). The expression of hsa-miR-195-5p was negatively correlated with RCAN3 (R=-0.19, p=0.01) and AP001486.2 (R=-0.26, p=0.00057), whereas the expression of hsa-miR-34a-5p was negatively correlated with PTPRJ (R=-0.23, p=0.0023) and AP006333.2 (R=-0.26, p=0.00057).

Fig 4: Overall survival and disease-free survival of RCAN3 and PTPRJ mRNA expression in Pan-Cancer.

Fig 5: PTPRJ and RCAN3 mRNA expression in TCGA and GSE19422 dataset. (A) PTPRJ and RCAN3 mRNA expression levels in PCPG were compared to normal adrenal gland tissue samples based on TCGA-PCPG database. (B) PTPRJ and RCAN3 mRNA expression levels in PCPG were compared to normal adrenal gland tissue levels based on the GSE19422 dataset.